Third Rock Ventures — Full Portfolio

Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.

BiotechCambridge, US

Robert Gould(Executive Officer, Director)inACAlex C. Sapir(President and Chief Executive Officer, Director)in

BoardAEAlan Ezekowitz(Director)inJames Geraghty(Director)James Collins(Director)

Board seatMLMark Levin· per SEC Form D

Co-investorsFOForesite CapitalSASanofi Ventures

A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.

BiotechArlington, US

JHJustin Hanes(Director)inKPKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTBTodd Bazemore(Executive Officer)inMIMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in

Board seatRTRobert Tepper· per SEC Form D

Co-investorsLOLongitude CapitalSRSR One Capital ManagementWEWellington ManagementYSYsios CapitalATAtlas VentureLULux Capital+1 more

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases.

BiotechSouth San Francisco, US

Bernard Coulie(Executive Officer, Director)inJohannes Hull(Executive Officer)Eric Lefebvre(Executive Officer)inKeith Cummings(Chief Financial Officer)inLCLily Cheung(Chief Human Resources Officer)inMKMinnie Kuo(Chief Operating Officer)in

Board seatCHCharles HomcyNENeil Exter· per SEC Form D · $62.1M raise · filed Jul 2018

Co-investorsMEMenlo VenturesAGAgent Capital

Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.

BiotechHealthtechMedical DevicesRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)

Board seatNENeil ExterBWBarbara Weber· per SEC Form D

Co-investorsBABain Capital Life SciencesFOForesite CapitalGEGen CapitalGVGV (Google Ventures)ILIllinois VenturesNENextech Invest+2 more

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

AHAlan Huang(Executive Officer)inACAdam Crystal(Executive Officer)inDBDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)

BoardBWBarbara Weber(Executive Officer, Director)in

Board seatAlexis BorisyReid Huber· per SEC Form D

Co-investorsFOForesite CapitalNENextech InvestNSNSG VenturesRORoche Venture Fund

Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases of the central nervous system, including Alzheimer's disease, ALS, and Parkinson's disease.

BiotechHealthtechLexington, US

TCTodd Carter(Executive Officer)inRobin Swartz(Executive Officer)inASAlfred Sandrock(Executive Officer, Director)PPPeter Pfreundschuh(Executive Officer)inNathan Jorgensen(Chief Financial Officer; Principal Financial Officer and Principal Accounting Officer)Steven Hyman(Director)

Board seatMLMark Levin· per SEC Form D

Co-investorsWEWellington ManagementARARCH Venture PartnersFIFidelity Investments

Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.

BiotechHealthtechMedical Devices

Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)CBCraig B. Thompson, M.D.(Founder)BGBrian Goff(Chief Executive Officer)in

Co-investorsARARCH Venture PartnersPOPortage VenturesFLFlagship VenturesSASamsara BioCapital

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.

BiotechHealthtechLongevityRichmond, US

KFKristen Fortney, PhD(Co-Founder, CEO)EMEric Morgen, MD(Co-Founder, COO)KFKristen Fortney(Founder)inEMEric Morgen(Founder)inDGDov Goldstein(Executive Officer)in

BoardPEPatrick Enright(Director)in

Co-investorsANAndreessen HorowitzELElad GilFEFelicis VenturesGRGreen Sands EquityIAIA Seed VenturesLOLongitude Capital+19 more

Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.

BiotechDeep TechMedical DevicesCambridge, US

FZFeng Zhang(Founder)inGCGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDLDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKBKatrine Bosley(Executive Officer, Director)inVMVic Myer(Executive Officer)in

Co-investorsECEcoR1 CapitalGVGV (Google Ventures)SOSofinnova VenturesVIViking GlobalATAtlas VentureDEDeerfield Management Company+2 more

Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a subcutaneously administered protein designed to deliver an essential protein to mitochondria in patients with Friedreich's ataxia, a rare genetic disease characterized by severe protein deficiency.

BiotechBala Cynwyd, US

Michael Celano(Chief Financial Officer)inCarole Ben Maimon, MD(President and CEO)Carole S. Ben-Maimon(President and Chief Executive Officer)Thomas O. Daniel(Director)Thomas Hamilton(Director)Frank E. Thomas(Director)

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

CHCharles Homcy(Director)JCJason Coloma(Chief Executive Officer)in

Co-investorsANAndreessen HorowitzARARCH Venture PartnersFOForesite CapitalFRFrazier Life SciencesGVGV (Google Ventures)HEHercules Capital, Inc.+9 more

Rapport is a biopharmaceutical company developing novel therapeutics.

BiotechHealthtechMedical Devices

ACAbe Ceesay(President)CGCheryl GaultinDr. SevignyAbraham N. Ceesay(President and Chief Executive Officer and Director)Steven Paul David Bredt(Founder)

Co-investorsARARCH Venture PartnersSOSofinnova VenturesCACapital GroupJOJohnson & Johnson Innovation – JJDC

Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.

AI & Machine LearningBiotechDeep TechCambridge, US

Donald A. Bergstrom(Executive Officer)inSKSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)

Co-investorsCOCommonweal VenturesECEcoR1 CapitalFOForesite CapitalNANat TurnerNENextech InvestSOSoftBank Vision Fund+2 more

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

DZDaphne Zohar(Founder, CEO & Board Member)inSPSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)MCMichael Chen(Executive Officer)inLGLana Gladstein(Executive Officer)inALAntony Loebel(Executive Officer)in

Co-investorsARARCH Venture PartnersFOForesite CapitalGEGeneral AtlanticHAHAWKTAILPUPureTech HealthSOSofinnova Ventures+4 more

Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.

AI & Machine LearningBiotechMedical DevicesSan Francisco, US

JDJennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)CTConnor Tsuchida(Scientific Cofounder)in

Co-investorsRARA CapitalSOSozo VenturesYOYosemite

Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications.

BiotechDeep TechHealthtechBoston, US

ABAndrea Ballabio(Founder)BLBeth Levine(Founder)Herbert Virgin(Founder)JHJames Hurley(Founder)in

Co-investorsASAstellas Venture Management LLCEIEisai Innovation, Inc.ONOno Venture Investment, Inc.THThe Column Group

Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.

AI & Machine LearningBiotechDeep TechHealthtech

JAJim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)JSJacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in

Co-investorsNENexTech VenturesPFPfizer VenturesNENextech InvestPFPfizer Venture InvestmentsSHShangBay Capital LLCAGAgent Capital

Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.

BiotechHealthtech

Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)MNMichael Naill(Senior Vice President, Process and Product Development)in

Co-investorsBABain Capital Life SciencesGVGV (Google Ventures)BIBiotechnology Value FundTHThe Engine Ventures

Strateos develops remote access laboratory software and automation platforms that enable scientists to design, execute, and analyze experiments through cloud-based robotics and control systems.

AI & Machine LearningBiotechDeep TechRoboticsSaaSMenlo Park, US

CKChris Krueger(Executive Officer)inMFMark Fischer-Colbrie(Executive Officer, Director)inDLDavid Lynch, PhD(Chief Executive Officer)MSMarc Siladi(Chief Operating Officer)in

BoardJoshua Wolfe(Director)AVArmen Vidian(Director)in

Co-investorsDCDCVC (Data Collective)LULux CapitalBLBlueStone Venture PartnersALAlumni VenturesDODolby Family VenturesHAHarmonix Fund+6 more

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.

BiotechHealthtechMental Health

Co-investorsGVGV (Google Ventures)BABain Capital Life Sciences

Vibe Bio funds and supports overlooked drug development programs by combining AI and capital to identify promising treatments and reduce funding gaps.

AI & Machine LearningBiotechEnterprise Software

ATAlok Tayi(CEO & Founder)inATAlok Tayi, Ph.D.(Co-founder and CEO)

Co-investors6T6th Man VenturesALAlleyCorpINInitialized CapitalLELerer HippeauUNUndeterred Capital64645 Ventures+1 more

BiotechSan Mateo, US

AFAnthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in

BoardArthur Pappas(Director)Liam Ratcliffe(Director)

Board seatKSKevin Starr· per SEC Form D

Co-investorsPAPappas CapitalDODomain AssociatesFIFidelity InvestmentsJEJennison Associates

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.

BiotechDigital HealthMedical DevicesCambridge, US

DADAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FZFENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)DWDavid Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)

Board seatMark Angelino· per SEC Form D · $215M raise · filed Nov 2021

Co-investorsARARCH Venture PartnersILIllumina VenturesONOno Venture Investment, Inc.TCTCG CrossoverALAlly Bridge GroupJAJanus Henderson Investors+4 more

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

IDIvana Djuretic(Founder)inAYAndy Yeung(Drug discovery)inYik Andy Yeung(Executive Officer, Director, Promoter)

Board seatJeffrey TongReid Huber· per SEC Form D

Co-investorsEMEmles Venture PartnersGOGoAhead VenturesMIMission Bay CapitalMIMission BiocapitalRARA CapitalWEWellington Management+9 more

Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.

BiotechHealthtechCambridge, US

Michael R. Cooper(Executive Officer)inJEJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)

Board seatRTRobert Tepper· per SEC Form D

Co-investorsAVAvoro Capital AdvisorsBABain Capital Life SciencesTHThe Column GroupVEVenrock

Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.

BiotechTewksbury, US

George J. Fazio(Executive Officer, Director)inDan B. Curtis(Executive Officer)

BoardPLPaul LaViolette(Director)inGBGerald Brunk(Director)inIYIrit Yaniv(Director)in

Board seatKevin GillisMLMark Levin· per SEC Form D

Co-investorsACAccelmed PartnersLULumira VenturesGEGeneral CatalystSVSV Health Investors

Element Science is a medical technology company that develops the Jewel, an FDA-approved adhesive-based wearable cardioverter defibrillator designed to protect patients at risk of sudden cardiac arrest.

AI & Machine LearningDigital HealthHardwareHealthtechMedical DevicesSan Francisco, US

UNUday N. Kumar(Executive Officer, Director)inUKUday Kumar(Founder)in

BoardRussell Hirsch(Director)KYKrishna Yeshwant(Director)inWilliam H. Kucheman(Director)

Board seatNENeil Exter· per SEC Form D

Co-investorsGVGV (Google Ventures)DEDeerfield Management CompanyQIQiming Venture Partners

BiotechCambridge, US

Ed Freedman(Executive Officer, Director)

BoardCPCary Pfeffer(Executive Officer, Director)in

PartnerCPCary Pfeffer· quoted

Board seatCHCharles HomcyRTRobert Tepper· per SEC Form D

Co-investorsNONovartis Venture Fund

Global Blood Therapeutics was a South San Francisco biopharmaceutical company founded in 2011 focused on treatments for sickle cell disease.

South San Francisco, US

JSJohn Schembri(Executive Officer)inTed W. Love(Executive Officer, Director)in

BoardCharles Homcy, M.D.(Director)

Board seatKSKevin Starr· per SEC Form D

Co-investorsAIAisling CapitalAVAvoro Capital AdvisorsRARA CapitalRIRidgeback CapitalWEWellington Management

Imaginab develops advanced imaging solutions for immuno-oncology that visualize immune cell activity and treatment response without invasive biopsies.

BiotechHealthtechMedical DevicesInglewood, US

Anna M. Wu(Executive Officer, Director)Jeffrey D. Quan(Executive Officer)Benjamin Chen(Executive Officer)inJennifer Keppler(President and Chief Operating Officer)Christian Behrenbruch(Chief Executive Officer)

BoardIsaac Bright(Director)

Board seatACAbbie Celniker· per SEC Form D · $9.5M raise · filed Apr 2016

Co-investorsCYCycad Group LLCRARaptor Group

Jounce Therapeutics was a Cambridge, MA clinical-stage biopharmaceutical company developing cancer immunotherapies, including antibodies targeting ICOS and LILRB2/ILT4, guided by a biomarker-driven discovery platform.

BiotechCambridge, US

KCKim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)inRMRichard Murray(Executive Officer, Director)

Board seatRKRobert KamenCPCary PfefferRTRobert Tepper· per SEC Form D

Co-investorsBOBoutique Venture PartnersGEGENERAL INCEPTIONNENextech InvestSOSofinnova VenturesVEVenture Capital Investment ManagementWEWellington Management

Kamal Therapeutics is developing an intravenous recombinant human decorin as a treatment for dystrophic epidermolysis bullosa.

BiotechHealthtechHingham, US

Mark de Souza(Executive Officer, Director)Alexander Silver(Director)Hal Landy(Director)Joff Masukawa(Director)Deborah Ramsdell(Executive Officer, Director)

Board seatPRPhilip Reilly· per SEC Form D · $17.3M raise · filed Nov 2025

Manifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs.

AI & Machine LearningBiotechDeep TechBoston, US

GKGleb Kuznetsov(Founder)inPOPierce Ogden(Founder)inGeorge Church(Founder)George M. Church(Founder)Shane Lofgren(Founder)

BoardJory Bell(Director)

Board seatSteven J. Kafka· per SEC Form D · $32.8M raise · filed Dec 2024

Co-investorsPLPlayground GlobalFIFifty YearsFPFPVHOHorizons VenturesTRTriatomic Capital

BiotechCambridge, US

RGRichard Gaynor, M.D.(Executive Officer)inRobert Ang, M.D.(Executive Officer)YAYasir Al-Wakeel(Executive Officer)inEric Lander(Director)Hugh Dowd(Executive Officer, Director)

BoardCary Pfeffer, M.D.(Director)

Board seatRKRobert KamenRTRobert Tepper· per SEC Form D

Co-investorsNENextech InvestSOSofinnova VenturesCLClal Biotechnology IndustriesWEWellington Management

HealthtechBedford, US

Christopher von Jako(Executive Officer, Director)inJudith M. Huber(Executive Officer)inCharles Carignan(Executive Officer, Director)Eric Swanson(Director)

BoardRHRussell Hirsch(Director)

Board seatMLMark Levin· per SEC Form D

Co-investorsPRProspect Venture Partners

BiotechMt. Arlington, US

Paul Chaney(Executive Officer, Director)

BoardDavid Guyer(Director)BPBruce Peacock(Director)KSKevin Starr(Director)inLutz Giebel(Director)

Board seatACAbbie Celniker· per SEC Form D

Co-investorsASAstellas Venture Management LLCAGAgent CapitalSVSV Health InvestorsSVSV Life Sciences

BiotechChestnut Hill, US

JIJoseph Italiano(Director)inJonathan Thon(Director)Sven Erik Karlsson(Executive Officer)Peter Finn(Executive Officer)

Board seatPRPhilip Reilly· per SEC Form D · $26.4M raise · filed Aug 2019

Co-investorsBOBoston Harbor AngelsQIQiming HealthcareVIVivo Capital

BiotechCambridge, US

Gad Soffer(Executive Officer)Ryan Cohlhepp(Executive Officer)J. Duncan Higgons(Director)Jeffrey Bluestone(Director)Dan Matloff(Executive Officer)Sanjay Keswani(Executive Officer, Director)

Board seatACAbbie CelnikerCPCary Pfeffer· per SEC Form D

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Keith Gottesdiener(Executive Officer, Director)inBHBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDMDavid Meeker(President and Chief Executive Officer)in

BoardETEdward T. Mathers(Director)inJSJonathan Silverstein(Director)in

Board seatNENeil Exter· per SEC Form D · $40M raise · filed Dec 2015

Co-investorsFOForesite CapitalHEHEALTHCARE ROYALTY PARTNERSNENew Enterprise Associates (NEA)PFPfizer Venture InvestmentsWEWellington ManagementOROrbiMed

Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.

AI & Machine LearningBiotechDeep TechSouth San Francisco, US

Robert Lefkowitz(Founder)Arthur Christopoulos(Founder)Patrick Sexton(Founder)RXRan Xiao(Executive Officer)inElizabeth Bhatt(Executive Officer)SSSamira Shaikhly(Executive Officer)in

Board seatJTJeffrey Tong· per SEC Form D

Co-investorsCACatalio Capital Management, LPRARA CapitalSASamsara BioCapitalVEVertex Ventures HC

Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.

BiotechBoston, US

TKTasuku Kitada(Executive Officer, Director, Promoter)inJBJacob Becraft(Executive Officer, Director, Promoter)inSamta Kundu(Executive Officer)in

BoardAAAla Alenazi(Director)inPEPegah Ebrahimi(Director)in

Board seatJKJeb Keiper· per SEC Form D · $120.1M raise · filed Mar 2026

Co-investorsJIJIC Venture Growth InvestmentsKIKinnevikPLPlayground GlobalAMAmgen VenturesANANRIFPFPV+3 more

A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.

BiotechDeep TechMedical DevicesWilmington, US

Liangxing Wu(Executive Officer, Director)inWenqing Yao(Executive Officer, Director)inTing Feng(Director)Wenqing Yao, Ph.D.(Founder & CEO)Liangxing Wu, Ph.D.(Co-Founder & SVP Drug Discovery)

Board seatRHReid Huber· per SEC Form D

Co-investorsNENextech InvestTHThe Innovation Space

Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.

BiotechDeep TechSouth San Francisco, US

Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)in

BoardMichael Goller(Director)PTPeter Thompson(Director)in

Board seatReid Huber· per SEC Form D

Co-investorsECEcoR1 CapitalOROrbiMedRARA CapitalNONovo Holdings

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

PTPatrick Trojer(President & Chief Executive Officer)in

Board seatJigar Raythatha· per SEC Form D · $120.1M raise · filed Dec 2025

Co-investorsASAscenta CapitalATAtlas VentureLILightspeed Venture PartnersRARA CapitalBEBessemer Venture PartnersPFPfizer Ventures+3 more

Ablexis develops the AlivaMab Mouse, a transgenic mouse platform for antibody drug discovery used by major pharmaceutical companies.

BiotechDeep Tech

Larry(CEO and Founder)

Co-investorsCACalifornia Technology VenturesPFPfizer Venture Investments

Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases.

BiotechHealthtechMedical DevicesMassachusetts, US

DODaniel Orlando(Chief Executive Officer)inTKTasos Konidaris(Executive Officer)inMartin Paz(Executive Officer)inRobert Gallotto(Executive Officer)inDTDaniel Tasse(Executive Officer, Director)inWilliam Scheinler(Executive Officer)in

Co-investorsHEHealthQuest CapitalBEBessemer Venture PartnersFRFrazier Life Sciences

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.

BiotechHealthtechMedical DevicesOslo, NO

RLRoy Larsen(Scientific Co-Founder)Øyvind Bruland(Scientific Co-Founder; SAB Chairman)Margaret Yu(Chief Medical Officer)inPhilippe Dasse(Chief Technical Officer)inADAmra Demirovic(Chief Human Resources Officer)inNHNicole Hadas(Chief Legal Officer)

Co-investorsB B Capital GroupB4B4 CapitalF-F-Prime CapitalSOSofinnova VenturesALAlexandriaB B Capital+2 more

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.

BiotechLongevityMedical DevicesCambridge, US

DMDavid Meek(Chief Executive Officer)inBRBrian Riley(President & Chief Technical Officer)inJLJoanne Lager(Chief Medical Officer)inWDWendy DiCicco(Chief Financial Officer)inACAdrian Chaisson(Chief of Staff)inJCJason Cole(Executive Officer)

Co-investorsARARCH Venture PartnersEAEaston CapitalRARA CapitalSASanofi VenturesTHThink+ Ventures Management, LlcWAWakestream Ventures+1 more

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Nick Lydon(Director)CSChristoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in

BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)

Co-investorsF-F-Prime CapitalFOForesite CapitalNENextech InvestRARA CapitalRIRidgeback CapitalRORoche Venture Fund+1 more

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

KSKen Song(Chairman, President and CEO)inKSKenneth Song, M.D.(Executive Officer, Director)AKArvind Kush(Executive Officer)TLTimothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsFOForesite CapitalLILifeSci Venture PartnersOROrbiMedSASamsara BioCapitalTCTCG CrossoverVEvenBio Partners+2 more

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

BiotechSan Mateo, US

GCGina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)

BoardAbraham Bassan(Director)

Co-investorsNENextech InvestRERed Tree VentureSASamsara BioCapitalWEWellington ManagementALAlly Bridge GroupJAJanus Henderson Investors+1 more

Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine.

HealthtechCambridge, US

TKTariq Kassum(Executive Officer, Director)inMBMichael Boretti(Executive Officer)inCLChristoph Lengauer(Executive Officer, Director)in

Co-investorsCACatalio Capital Management, LPFAFast Track InitiativeGVGV (Google Ventures)ALAlexandriaAMAmplitude Venture CapitalCACasdin Capital

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.

BiotechHealthtechCambridge, US

Co-investorsCACatalio Capital Management, LPCUCure VenturesVIVivo CapitalBRBrightEdgeCACatalio Capital ManagementNONovo Holdings

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

KKKazuki Kamiya(CEO)SISatoru Ichihara(COO)SHShinya Hayashi(CSO)HIHidefumi Iwaki(CFO)TSTomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANANOBAKACACARTA VENTURES, Inc.SPSpiral VenturesAGAgent CapitalCACasdin CapitalINInvus+2 more

Flare is a Shopify app that calculates location-specific delivery dates, methods, cut-off times and rates at checkout based on a customer's exact postcode or ZIP code, down to individual zones.

E-commerceLogistics & Supply ChainRetail TechSaaSLondon, GB

DPDaniel Parekh-Hill(CEO)inAlex Hooper(CTO)in

Co-investorsENEntrepreneur FirstAGAgent CapitalBABase10 PartnersCACasdin CapitalINInovia CapitalINInvus+3 more

Foundation Medicine is a precision medicine company that develops comprehensive genomic profiling and companion diagnostic tests for cancer and other diseases.

BiotechDigital HealthMedical DevicesBoston, US

Alexis Borisy(Founder)Eric Lander(Founder)Levi Garraway(Founder)Todd Golub(Founder)

Co-investorsGVGV (Google Ventures)KHKhosla VenturesKLKleiner PerkinsNSNSG VenturesRIRidgeback CapitalRORoche Venture Fund+2 more

Genetix Biotherapeutics develops gene addition therapies that use a patient's own cells to treat the underlying cause of rare diseases with a single dose, with a focus on hematology conditions such as sickle cell disease.

BiotechDeep TechHealthtech

Co-investorsSKSK Capital Partners

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

DKDaphne Koller(Founder)inDVDuane Valz(General Counsel)inMRMary Rozenman(Chief Financial Officer)in

BoardRNRobert Nelsen(Director)VPVijay Pande(Director)in

Co-investorsANAndreessen HorowitzARARCH Venture PartnersDEDeviation CapitalFOForesite CapitalGVGV (Google Ventures)HOHOF Capital+9 more

Acquired by Lisata Therapeutics alongside a $225 million concurrent private placement.

BiotechSan Francisco, US

Mark Joing(Executive Officer)inChristine Garrett(Executive Officer)inJosh Lehrer(Executive Officer, Director)inEthan Weiss(Executive Officer)inCaitlin Murray(Executive Officer)

BoardJeff Tong(Director)

Co-investorsALAlpha Wave GlobalSOSofinnova VenturesVEvenBio PartnersFOForbion

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAPAsit Parikh(Chief Executive Officer)in

Co-investorsLILifeSci Venture PartnersNENextech InvestALAlexandriaCACasdin CapitalCRCreacion VenturesGOGoldman Sachs+3 more

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

ATArthur T. Sands(Executive Officer, Director)inGMGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

BoardDGDavid Goeddel(Director)inMark Goldsmith(Director)

Co-investorsBABain Capital Life SciencesECEcoR1 CapitalFOForesite CapitalGEGeneral AtlanticSOSofinnova VenturesTHThe Column Group+1 more